N
News Analysis
dailypolitical.com

www.dailypolitical.com ·

Neutral

immix biopharma nasdaqimmx issues quarterly earnings results misses estimates by 0 04 eps

TAX_DISEASE_CANCERWB_1431_CANCERTAX_FNCACT_CANDIDATEAFFECT

All NewsRead the full story on dailypolitical.com

The full article is on the original publisher site. This page only shows the headline and a very short excerpt.

AI insight

AI-generated

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biotech company. The earnings miss is a company-specific event with no disclosed commercial mechanism (no product revenue, no pipeline catalyst, no supply chain impact). The stock rose despite the miss, suggesting market focus on other factors. No direct sector-wide or supply-chain implications.

Signals our AI researcher identified

Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.

  • Immix Biopharma reported Q1 2026 EPS loss of $0.18, missing consensus of $0.14 by $0.04.
  • Shares rose $0.21 to $9.75 on volume of 661,183 shares.
  • Market cap is $516.85 million; 52-week range $1.87–$11.61.
  • Institutional investors including Vanguard and Tocqueville increased holdings.
  • Consensus price target is $18.25 with 'Moderate Buy' rating.
immix biopharma nasdaqimmx issues quarterly earnings results misses estimates by 0 04 eps | dailypolitical.com — News Analysis